ROS-driven structural and functional fibrinogen modifications are reverted by interleukin-6 inhibition in Giant Cell Arteritis
Copyright © 2023 The Authors. Published by Elsevier Ltd.. All rights reserved..
BACKGROUND: Cranial and extra-cranial vascular events are among the major determinants of morbidity and mortality in Giant Cell Arteritis (GCA). Vascular events seem mostly of inflammatory nature, although the precise pathogenetic mechanisms are still unclear. We investigated the role of oxidation-induced structural and functional fibrinogen modifications in GCA. The effects of the anti-IL6R tocilizumab in counteracting these mechanisms were also assessed.
MATERIALS AND METHODS: A cross-sectional study was conducted on 65 GCA patients and 65 matched controls. Leucocyte reactive oxygen species (ROS) production, redox state, and fibrinogen structural and functional features were compared between patients and controls. In 19 patients receiving tocilizumab, pre vs post treatment variations were assessed.
RESULTS: GCA patients displayed enhanced blood lymphocyte, monocyte and neutrophil ROS production compared to controls, with an increased plasma lipid peroxidation and a reduced total antioxidant capacity. This oxidative impairment resulted in a sustained fibrinogen oxidation (i.e. dityrosine content 320 (204-410) vs 136 (120-176) Relative Fluorescence Units (RFU), p < 0.0001), with marked alterations in fibrinogen secondary and tertiary structure [intrinsic fluorescence: 134 (101-227) vs 400 (366-433) RFU, p < 0.001]. Structural alterations paralleled a remarkable fibrinogen functional impairment, with a reduced ability to polymerize into fibrin and a lower fibrin susceptibility to plasmin-induced lysis. In patients receiving tocilizumab, a significant improvement in redox status was observed, accompanied by a significant improvement in fibrinogen structural and functional features (p < 0.001).
CONCLUSIONS: An impaired redox status accounts for structural and functional fibrinogen modifications in GCA, suggesting a potential role of tocilizumab for cardiovascular prevention in GCA.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:230 |
|---|---|
| Enthalten in: |
Thrombosis research - 230(2023) vom: 15. Okt., Seite 1-10 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Bettiol, Alessandra [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
9001-31-4 |
|---|
| Anmerkungen: |
Date Completed 02.10.2023 Date Revised 12.10.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.thromres.2023.08.011 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM360973973 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM360973973 | ||
| 003 | DE-627 | ||
| 005 | 20231226084150.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.thromres.2023.08.011 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1203.xml |
| 035 | |a (DE-627)NLM360973973 | ||
| 035 | |a (NLM)37598635 | ||
| 035 | |a (PII)S0049-3848(23)00236-0 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Bettiol, Alessandra |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a ROS-driven structural and functional fibrinogen modifications are reverted by interleukin-6 inhibition in Giant Cell Arteritis |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 02.10.2023 | ||
| 500 | |a Date Revised 12.10.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 The Authors. Published by Elsevier Ltd.. All rights reserved. | ||
| 520 | |a BACKGROUND: Cranial and extra-cranial vascular events are among the major determinants of morbidity and mortality in Giant Cell Arteritis (GCA). Vascular events seem mostly of inflammatory nature, although the precise pathogenetic mechanisms are still unclear. We investigated the role of oxidation-induced structural and functional fibrinogen modifications in GCA. The effects of the anti-IL6R tocilizumab in counteracting these mechanisms were also assessed | ||
| 520 | |a MATERIALS AND METHODS: A cross-sectional study was conducted on 65 GCA patients and 65 matched controls. Leucocyte reactive oxygen species (ROS) production, redox state, and fibrinogen structural and functional features were compared between patients and controls. In 19 patients receiving tocilizumab, pre vs post treatment variations were assessed | ||
| 520 | |a RESULTS: GCA patients displayed enhanced blood lymphocyte, monocyte and neutrophil ROS production compared to controls, with an increased plasma lipid peroxidation and a reduced total antioxidant capacity. This oxidative impairment resulted in a sustained fibrinogen oxidation (i.e. dityrosine content 320 (204-410) vs 136 (120-176) Relative Fluorescence Units (RFU), p < 0.0001), with marked alterations in fibrinogen secondary and tertiary structure [intrinsic fluorescence: 134 (101-227) vs 400 (366-433) RFU, p < 0.001]. Structural alterations paralleled a remarkable fibrinogen functional impairment, with a reduced ability to polymerize into fibrin and a lower fibrin susceptibility to plasmin-induced lysis. In patients receiving tocilizumab, a significant improvement in redox status was observed, accompanied by a significant improvement in fibrinogen structural and functional features (p < 0.001) | ||
| 520 | |a CONCLUSIONS: An impaired redox status accounts for structural and functional fibrinogen modifications in GCA, suggesting a potential role of tocilizumab for cardiovascular prevention in GCA | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Fibrinogen | |
| 650 | 4 | |a Giant cell arteritis | |
| 650 | 4 | |a Reactive oxygen species | |
| 650 | 4 | |a Thrombosis | |
| 650 | 4 | |a Vasculitis | |
| 650 | 7 | |a Interleukin-6 |2 NLM | |
| 650 | 7 | |a Reactive Oxygen Species |2 NLM | |
| 650 | 7 | |a Fibrinogen |2 NLM | |
| 650 | 7 | |a 9001-32-5 |2 NLM | |
| 650 | 7 | |a Hemostatics |2 NLM | |
| 650 | 7 | |a Fibrin |2 NLM | |
| 650 | 7 | |a 9001-31-4 |2 NLM | |
| 700 | 1 | |a Argento, Flavia Rita |e verfasserin |4 aut | |
| 700 | 1 | |a Fini, Eleonora |e verfasserin |4 aut | |
| 700 | 1 | |a Bello, Federica |e verfasserin |4 aut | |
| 700 | 1 | |a Di Scala, Gerardo |e verfasserin |4 aut | |
| 700 | 1 | |a Taddei, Niccolò |e verfasserin |4 aut | |
| 700 | 1 | |a Emmi, Giacomo |e verfasserin |4 aut | |
| 700 | 1 | |a Prisco, Domenico |e verfasserin |4 aut | |
| 700 | 1 | |a Becatti, Matteo |e verfasserin |4 aut | |
| 700 | 1 | |a Fiorillo, Claudia |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Thrombosis research |d 1974 |g 230(2023) vom: 15. Okt., Seite 1-10 |w (DE-627)NLM000010839 |x 1879-2472 |7 nnns |
| 773 | 1 | 8 | |g volume:230 |g year:2023 |g day:15 |g month:10 |g pages:1-10 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.thromres.2023.08.011 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 230 |j 2023 |b 15 |c 10 |h 1-10 | ||